BCM
INBX icon

Bridgeway Capital Management’s Inhibrx INBX Stock Holding History

Bridgeway Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379K Sell
4,000
-2,500
-38% -$250K 0.01% 917
2026
Q1 		$437K Sell
6,500
-2,500
-28% -$185K 0.01% 845
2025
Q4 		$711K Sell
9,000
-7,500
-45% -$511K 0.01% 760
2025
Q3 		$556K Hold
16,500
– – 0.01% 783
2025
Q2 		$235K Buy
+16,500
New +$213K 0.01% 923

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bridgeway Capital Management's INBX Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Inhibrx (INBX) stake by 38% in Q2 2026, selling an estimated $250K and leaving 4,000 shares worth $379K. The position accounts for 0.01% of the portfolio, ranked #917.

Bridgeway Capital Management first reported a position in INBX in Q2 2025 and has held it in 5 quarters since. The position peaked at $711K in Q4 2025. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Bridgeway Capital Management held 4,000 shares of Inhibrx worth $379K as of Q2 2026.
  • Bridgeway Capital Management sold 2,500 Inhibrx shares in Q2 2026, an estimated $250K.
  • Inhibrx made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #917 holding.
  • Bridgeway Capital Management first reported a position in Inhibrx in Q2 2025 and has held it in 5 quarters since.
  • Bridgeway Capital Management's Inhibrx position peaked at $711K in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.